Anupam Rasayan India Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/rqv9dz229ptrtzlqk7z169r5.pdf

Key Takeaways


Demand & Revenue Drivers

Anand Desai: "Our order book remains strong, despite the challenging environment giving us a good visibility of robust growth for the current financial year, and we are positive on maintaining our guidance of 20% growth with similar margins."

Working Capital & Balance Sheet

Vishal Thakkar: "I would put it this way that if you see Anand Desai is the founding promotor, he has been increasing his shareholding in the company. And that has been the primary driver for this press."

Fluorination & Portfolio Evolution


Margins & Cost Structure

Vishal Thakkar: "I would really tend to guide at 26% to 28%, though we have done 29%, but I would always caution that 26% to 28% is a fair guidance that I would want to give. If we perform better, we would definitely be happy and that's our endeavour as a management that we improve every single bps of my EBITDA margin."

Competitive Position & External Environment

Vishal Thakkar: "We believe that it's a quarter or two quarter that they would be done with that stock and the new stock will come into the market where they will have to also price the products as per the current market prices."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth20% growth with similar marginsFY24
Debtor normalizationDebtor days to return to normal levelsNext two quarters
Preferential issue proceedsPromoter funds receivedFirst/second week of December 2023
Fluorination revenue mixReach ~20% of revenueFY24 year-end
Fluorination revenue mixReach 25–30% of expanded revenue baseLong-term (no date)
Capex spendBalance ₹670 crores deployedNext 6–9 months
FY25 capex characterMaintenance and debottlenecking only, no large capacity additionFY25
Molecule launchesFive molecules in pipeline launchedNext two quarters
New LOI/contract revenue~₹1,000 crores added, staggeredOver 3–4 years
Carbon neutralityNet carbon neutral on energy consumptionBy 2027
EBITDA margin26–28% on standalone, similar consolidatedOngoing

Key Metrics

MetricQ2 FY24
Total revenue₹396 cr, up 3% YoY from ₹383 cr in Q2 FY23
Total revenue (H1 FY24)₹794 cr, up 11% YoY from ₹718 cr in H1 FY23
EBITDA (including other income)₹111 cr, up 10% YoY from ₹101 cr in Q2 FY23
EBITDA margin28%
EBITDA (H1 FY24, including other income)₹225 cr, up 18% YoY from ₹190 cr in H1 FY23
EBITDA margin (H1 FY24)28%
Profit after tax₹49 cr, up 2% YoY from ₹48 cr in Q2 FY23
Profit after tax (H1 FY24)₹101 cr, up 12% YoY from ₹90 cr in H1 FY23
Revenue growth guidance20% for FY24, with similar margins
EBITDA margin guidance26% to 28% on standalone basis, consolidated similar historically
LOIs and contracts signed₹7,669 cr as of September 30, 2023
New molecules launched in FY245 (3 in Q2), total products now 58; 5 more planned in coming two quarters
Revenue from fluorination~15% of revenue in H1 FY24, expected ~20% by year-end, long-term target 25% to 30%
Domestic vs export revenue split45% domestic, 55% export
Top 10 customer concentration83% of total revenue, across 24 products
Cash equivalents₹404 cr as of September 30, 2023
Preferential issue₹550 cr, primarily to retire long-term debt, EPS accretive
Capex announced₹670 cr total, ₹234 cr incurred to date, balance over next 6 to 9 months
Revenue potential from current capex₹1,700 to ₹1,800 cr from existing plants; total capex plus other investments implies ₹2,000 to ₹3,000 cr revenue
New contracts/LOIs expected addition~₹1,000 cr in revenue over 3 to 4 years
Contractual or contractual-behaviour revenue~70%-plus of total revenue
Six-month pricing agreements status~60% of contractor revenue covered, a couple pending